Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)

NCT02573181 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

253

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Infections

Interventions

BIOLOGICAL: V114
BIOLOGICAL: Prevnar 13™

Sponsor

Merck Sharp & Dohme LLC